25-Hydroxyvitamin D Levels and Risk of Ischemic Heart Disease, Myocardial Infarction, and Early Death
Population-Based Study and Meta-Analyses of 18 and 17 Studies
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Objective—We tested the hypothesis that reduced plasma 25-hydroxyvitamin D associates with increased risk of ischemic heart disease, myocardial infarction, and early death.
Methods and Results—We measured baseline plasma 25-hydroxyvitamin D in 10 170 women and men from the Danish general population without vitamin D–fortified food. During 29 years of follow-up, 3100 persons developed ischemic heart disease, 1625 myocardial infarction, and 6747 died. Decreasing plasma 25-hydroxyvitamin D levels were associated with increasing risk of ischemic heart disease, myocardial infarction, and early death as a function of seasonally adjusted percentile categories (P for trend, 2×10−4–3×10–53). Comparing individuals with plasma 25-hydroxyvitamin D levels at the 1st to 4th percentile with individuals with levels at the 50th to 100th percentile, the multivariable adjusted risk was increased by 40% (95% CI, 14%–72%) for ischemic heart disease, by 64% (25%–114%) for myocardial infarction, by 57% (38%–78%) for early death, and by 81% (40%–135%) for fatal ischemic heart disease/myocardial infarction. In the meta-analyses of 18 and 17 studies, risk of ischemic heart disease and early death were increased by 39% (25%–54%) and 46% (31%–64%) for lowest versus highest quartile of 25-hydroxyvitamin D level.
Conclusion—We observed increasing risk of ischemic heart disease, myocardial infarction, and early death with decreasing plasma 25-hydroxyvitamin D levels. These findings were substantiated in meta-analyses.
- Received February 17, 2012.
- Accepted July 30, 2012.
- © 2012 American Heart Association, Inc.